Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking and Finance Review

Global Banking & Finance Review

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2025 GBAF Publications Ltd - All Rights Reserved.

    Editorial & Advertiser disclosure

    Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Headlines > Novo Nordisk woes prompt Denmark to slash country's 2025 growth forecast
    Headlines

    Novo Nordisk woes prompt Denmark to slash country's 2025 growth forecast

    Novo Nordisk woes prompt Denmark to slash country's 2025 growth forecast

    Published by Global Banking and Finance Review

    Posted on August 28, 2025

    Featured image for article about Headlines

    (Reuters) -Denmark has cut its 2025 economic growth forecast to 1.4% from 3%, citing weaker prospects for pharmaceutical giant Novo Nordisk and tariffs on Danish goods exported to the U.S., the country's economy ministry said on Friday. 

    "The pharmaceutical industry is increasingly challenged by competition in the markets for weight loss products, which has dampened growth expectations in the industry," the ministry said in a statement. 

    A Novo Nordisk spokesperson declined to comment.

    The Nordic country of six million people has benefited from the rapid expansion of Novo Nordisk, maker of the Wegovy weight loss drug and the Ozempic diabetes treatment. Last year, Denmark's economic growth ranked among the highest in Europe, in part driven by Novo Nordisk, which accounted for one-fifth of the country's employment growth.

    Denmark, also home to large companies like shipping group Maersk, brewer Carlsberg, toymaker Lego and wind turbine maker Vestas, has an export-oriented economy that is highly sensitive to global developments but is helped by a large savings surplus and solid public finances.

    Earlier this month, Novo Nordisk cut its full-year sales and operating profit forecasts for the second time this year, as the maker of Wegovy struggles to convince investors it can remain competitive in the obesity drug boom against U.S. rival Eli Lilly. The company, which employs around 34,000 people in Denmark, is facing layoffs after having almost doubled its total workforce over the last five years.

    The ministry said that tariffs on goods imported into the United States, Denmark's biggest export market, would also dampen growth. Exports to the United States saw a significant decline in the first half of the year, after a spike in the last six months of 2024, it said. 

    Exports are now forecast to grow by just 0.9% in 2025 compared to a May forecast of 4.3%.

    However, the ministry increased its GDP growth forecast for 2026 to 2.1% from 1.4% as forecast in May, partly driven by an expectation of higher private and public spending.

    (Reporting by Soren Sirich Jeppesen, Jacob Gronholt-Pedersen and Bipasha Dey in Bengaluru; Editing by Cynthia Osterman, William Maclean)

    Related Posts
    Novartis, Roche back US efforts to lower drug costs amid talk of pricing deal
    Novartis, Roche back US efforts to lower drug costs amid talk of pricing deal
    Saudi, French and U.S. officials push Hezbollah disarmament plan
    Saudi, French and U.S. officials push Hezbollah disarmament plan
    Russia sentences Briton who it says fought for Ukraine to 13 years in a prison camp
    Russia sentences Briton who it says fought for Ukraine to 13 years in a prison camp
    Ukrainian negotiators to meet US team on Friday, Saturday, Zelenskiy says
    Ukrainian negotiators to meet US team on Friday, Saturday, Zelenskiy says
    Court hearing adjourned in strangulation case involving UK's Duke of Marlborough
    Court hearing adjourned in strangulation case involving UK's Duke of Marlborough
    Ukraine says 180,000 consumers were left without power after Russian overnight attack
    Ukraine says 180,000 consumers were left without power after Russian overnight attack
    China says it is granting new, streamlined rare earth export licences
    China says it is granting new, streamlined rare earth export licences
    Romania to raise minimum wage by 6.8% from July
    Romania to raise minimum wage by 6.8% from July
    Coinbase appoints UK ex-finance minister George Osborne to run advisory council
    Coinbase appoints UK ex-finance minister George Osborne to run advisory council
    EU must reform or risk irrelevance, Blair and Dimon say
    EU must reform or risk irrelevance, Blair and Dimon say
    Russian attack on Ukraine's central Cherkasy injures six, causes blackouts, governor says
    Russian attack on Ukraine's central Cherkasy injures six, causes blackouts, governor says
    Europe's auto industry future may be electric even after EU climbdown
    Europe's auto industry future may be electric even after EU climbdown

    Why waste money on news and opinions when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    More from Headlines

    Explore more articles in the Headlines category

    Factbox-Can Ukraine survive without the EU's 'reparation loan'?

    Factbox-Can Ukraine survive without the EU's 'reparation loan'?

    EU leaders face crunch decision on using frozen Russian assets for Ukraine

    EU leaders face crunch decision on using frozen Russian assets for Ukraine

    Analysis-Return of 'Make Europe Great Again' trades hinges on German comeback

    Analysis-Return of 'Make Europe Great Again' trades hinges on German comeback

    Belarus' Lukashenko says US admission of failure to overturn re-election could revive relations

    Belarus' Lukashenko says US admission of failure to overturn re-election could revive relations

    Ukrainian drones kill three people in Russia's Rostov region, authorities say

    Ukrainian drones kill three people in Russia's Rostov region, authorities say

    Shares in South Korea's LGES drop more than 7% after Ford cancels EV battery deal

    Shares in South Korea's LGES drop more than 7% after Ford cancels EV battery deal

    Factbox-What we know about the shooting victims at Sydney's Bondi Beach Jewish event

    Factbox-What we know about the shooting victims at Sydney's Bondi Beach Jewish event

    Australia promises new hate laws as youngest Bondi Beach shooting victim is laid to rest

    Australia promises new hate laws as youngest Bondi Beach shooting victim is laid to rest

    UN, aid groups warn Gaza operations at risk from Israel impediments

    UN, aid groups warn Gaza operations at risk from Israel impediments

    IMF says Moldova's economy has unique growth opportunity, but reforms needed

    IMF says Moldova's economy has unique growth opportunity, but reforms needed

    UK firm Awendio Solaris plans $725 million solar plant with indigenous groups in Canada

    UK firm Awendio Solaris plans $725 million solar plant with indigenous groups in Canada

    AbbVie, several other pharma companies near MFN deal with Trump, sources say

    AbbVie, several other pharma companies near MFN deal with Trump, sources say

    View All Headlines Posts
    Previous Headlines PostTrading Day: Fed hopes lift stocks, clip dollar
    Next Headlines PostAnalysis-Trump's options to ease Russia sanctions limited compared to Europe's